PHARMACOLOGICAL CORRECTION OF THE INFLAMMATION IN EXPERIMENTAL PROSTATITE
DOI:
https://doi.org/10.21856/j-PEP.2019.2.12Keywords:
chronic non-bacterial prostatitis/chronic pelvic pain syndrome, inflammation, chondroitin sulfate, Bioglobin-U, Tribestan, ProstaplantAbstract
Nowadays, the searching of etiopathogenetic factors and effective methods of treatment of non-bacterial prostatitis is actual task. The purpose of our research is to assess the impact of stimulants of metabolic processes on the inflammation by C-reactive protein concentration, white blood cells number and erythrocyte sedimentation rate in rats under the conditions of experimental prostatitis. Non-bacterial prostatitis have been caused by double rectal dosing of 1 ml of a mixture based on a 10 % solution of dimexide in water and turpentine in a 4:1 ratio (turpentine prostatitis model) to male rats. The drugs of chondroitin sulfate, chondroitin sulfate and Tribestan, Tribestan, Bioglobin-U, Prostaplant have been administrated during 14 days. The concentration of C-reactive protein have been determined using a latex reagent, the number of leukocytes - in the Goryaev chamber, erythrocyte sedimentation rate — according to the Panchenkov method. All researched drugs have anti-inflammatory properties under the conditions of turpentine prostatitis model. According to the effectiveness of reducing the concentration of C-reactive protein, leukocytosis and erythrocyte sedimentation rate , they can be placed in the following sequence: Chondroitin Sulfate, Bioglobin-U, Tribestan, Prostaplant, Chondroitin Sulfate + Tribestan (combination). In conclusion, Chondroitin Sulfate, Bioglobin-B, Tribestan, Prostaplant, Chondroitin Sulfate + Tribestan (combination) reduce the expressivenes of inflammation. Chondroitin sulfate and Bioglobin-U demonstrate more stronger anti-inflammatory properties.
References
Kumsar S, Kose O, Aydemir H, et al. Int Braz J Urol 2016; 42 (3): 540-545. https://doi.org/10.1590/S1677-5538.IBJU.2015.0254.
Krieger JN, Lee SWH, Jeon J, et al. Int J Antimicrob Agents 2008; 31 (1): S85-S90. https://doi.org/10.1016/j.ijantimicag.2007.08.02.
Holt JD, Garrett WA, McCurry TK, Teichman JM. Am Fam Physician 2016; 93 (4): 290-296.
Cohen D, Gonzalez J, Goldstein I. Sex Med Rev 2016; 4 (1): 53-62. https://doi.org/10.1016/j.sxmr.2015.10.001.
Magistro G, Wagenlehner FM, Grabe M, et al. Eur Urol 2016; 69 (2): 286-297. https://doi.org/10.1016/j.eururo.2015.08.061.
Huang BX, Cao WL, Huang X, et al. Zhonghua Nan Ke Xue 2015; 21 (1): 23-30.
Monteiro CM, Pinheiro LF, Izar MC, et al. Braz J Med Biol Res 2010; 43 (3): 297-302.
Novikova EG, Seljatickaja VG, Lutov JuV. Sovremennye Problemy Nauki i Obrazovanija 2011;5, available at: https://www.science-education.ru/ru/article/view?id=4860.
Gianni Paulis. Res Rep Urol 2018; 10: 75-87. https://doi.org/10.2147/RRU.S170400.
Polackwich AS, Shoskes DA. Prostate Cancer Prostatic Dis 2016; 19 (2): 132-138. https://doi.org/10.1038/pcan.2016.8.
Patent № 2182370. Sposob modelirovanija hronicheskogo prostatita.
Patent 38911 Sposib vyznachennja koncentracii' S-reaktyvnogo bilka ekspres-metodom.
Glans S. Mediko-biologicheskaja statistika, Moskva, 1998: 459 p.
Chen Y, Li J, Hu Y, et al. Sci Rep 2017; 7 (1): 1-12. https://doi.org/10.1038/s41598-017-09751-8.
Maeda N. Front Neurosci 2015;9: 98. https://doi.org/10.3389/fnins.2015.00098.
Kobayashi T, Kakizaki I, Nozaka H, Nakamura T. Biochem Biophys Rep 2016;9: 72-78. https://doi.org/10.1016/j.bbrep.2016.11.009.
Jacenko OV. ScienceRise: Medical Science 2017; 5 (13): 32-36.
Bioglobin-U (Bioglobinum-U): Obshhaja harakteristika, available at: http://www.biolik.com.ua/produc.php?pr=22145.
ISSN 
ISSN 
